News this week that the Japanese company Maruho is to acquire Pennsylvania based Cutanea Life Sciences. Cutanea Life Sciences is developing Omiganan as a treatment for rosacea.
Maruho Co., Ltd. Acquires Cutanea Life Sciences, Inc.
Cutanea to Become a Wholly-Owned Subsidiary of Maruho
OSAKA, Japan, Feb 13, 2012 (GlobeNewswire via COMTEX) — Mr. Koichi Takagi, President and CEO of Maruho Co., Ltd, headquartered in Kita-ku, Osaka, Japan, announced today the acquisition of Cutanea Life Sciences (CLS), a privately held dermatology development company based in Villanova, Pennsylvania USA. CLS will become a wholly-owned subsidiary of Maruho. Mr. Takagi stated that the acquisition of CLS represents an important step in building Maruho’s infrastructure and capabilities in the United States.
We learnt in 2006 that Cutanea were trialing Omiganan for rosacea. The treatment is known as a topical cationic peptide. This treatment has anti-inflammatory properties that were promising for acne. Now the developers are planning to trial it next year against rosacea.
CLS001 (omiganan pentahydrochloride) is described as “a novel cationic antimicrobial peptide in development for the treatment of inflammatory papules and pustules associated with rosacea”.
Further; “CLS001 is formulated in an aqueous based topical gel. It is designed to provide cosmetic elegance with minimal irritation. Cutanea believes that CLS001 will offer the following advantages: rapid onset of action, antimicrobial and anti-inflammatory activity, and non-detectable systemic absorption, thereby causing minimal adverse side effects.”
Omiganan is in the list of 9 New Rosacea Treatments.
Related Articles
- Cutanea Life Sciences files IPO to fund Omiganan development
- What’s Hot in New Rosacea Treatments?
- Trial Watch: New Treatments Coming Soon
- Why Do New Drugs take SO LONG to be Developed?
- 9 New Drugs in Development for Rosacea
